# US 2005/0238607 A1 · FGF-5 supported and binding peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0238607 A1
- Document ID: US20050238607A1
- Status: Published application
- Kind: A1
- Application number: 10/984,410
- Filed: 2004-11-08
- Published: 2005-10-27
- Earliest claimed: 2003-11-06
- Assignees: Genencor International, Inc.
- Inventors: Anthony Day; Christopher Murray; Scott Power; Beverley Rider Turnquest
- Web page: https://patentgrep.com/patent/US20050238607A1

## CPC

- C07K 14/81: Protease inhibitors
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/811: {Serine protease (E.C. 3.4.21) inhibitors}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides peptides and supported peptides that bind to FGF-5.

## Claims

### Claim 1

A composition comprising at least one peptide selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, and 14, wherein said peptide binds to a fibroblast growth factor.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said peptide is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, and 13.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said peptide is expressed in a protease resistant scaffold.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said scaffold is a protease inhibitor.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said protease inhibitor is selected from the group consisting of Bowman-Birk Inhibitor, soybean trypsin inhibitor, and Eglin chymotrypsin inhibitor.

### Claim 6 (depends on 3)

The composition of claim 3, wherein said protease resistant scaffold and said peptide comprise a fusion protein.

### Claim 7 (depends on 1)

A cosmetic or pharmaceutical composition comprising said at least one peptide of claim 1.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said composition is capable of modulating hair growth.

### Claim 9 (depends on 7)

The composition of claim 7, wherein said composition further comprises a scaffold.

### Claim 10

A method for modulating hair growth comprising:
i) providing a composition comprising a peptide contained within a scaffold;
ii) providing a subject to be treated; and
iii) applying said composition to said subject in an area in which hair growth modulation is desired.

### Claim 11 (depends on 10)

The method of claim 10, wherein said peptide binds to a fibroblast growth factor.

### Claim 12 (depends on 11)

The method of claim 11, wherein said fibroblast growth factor (FGF) is FGF-5.

### Claim 13 (depends on 10)

The method of claim 10, wherein said scaffold is selected from the group consisting of Bowman-Birk inhibitor, soybean trypsin inhibitor, and Eglin chymotrypsin inhibitor.

### Claim 14 (depends on 10)

The method of claim 10, wherein said peptide is selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, and 14.

### Claim 15 (depends on 10)

The method of claim 10, wherein said peptide is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, and 13.

### Claim 16 (depends on 1)

A method for decreasing the activity of a fibroblast growth factor comprising the steps of:
i) providing a subject; and
ii) administering the composition of claim 1 to said subject, under conditions such that the activity of said fibroblast growth factor is decreased.

### Claim 17 (depends on 16)

The method of claim 16, wherein said fibroblast growth factor is FGF-5.

### Claim 18

A composition comprising an FGF-5 peptide sequence selected from the group of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 15-43, 45-65, 68-84, 86, 88, 90, 92, 24, 26, 98, and 100.
